Exact Sciences Stock (NASDAQ:EXAS)
Previous Close
$66.41
52W Range
$40.62 - $79.62
50D Avg
$60.96
200D Avg
$58.95
Market Cap
$12.63B
Avg Vol (3M)
$2.64M
Beta
1.27
Div Yield
-
EXAS Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Performance
Peer Comparison
Ticker | Company |
---|---|
GH | Guardant Health, Inc. |
TMO | Thermo Fisher Scientific Inc. |
DHR | Danaher Corporation |
CDNA | CareDx, Inc |
NTRA | Natera, Inc. |
A | Agilent Technologies, Inc. |
TWST | Twist Bioscience Corporation |
CSTL | Castle Biosciences, Inc. |
CRL | Charles River Laboratories International, Inc. |
ILMN | Illumina, Inc. |
MYGN | Myriad Genetics, Inc. |